Pharmos Corp
Change company Symbol lookup
Select an option...
PARS Pharmos Corp
VGT Vanguard Information Technology Index Fund ETF Shares
USA Liberty All-Star Equity
TRMT Tremont Mortgage Trust
TGT Target Corp
T AT&T Inc
STT-D State Street Corp
SPOT Spotify Technology SA
SPDW SPDR® Portfolio Developed World ex-US ETF

Health Care : Pharmaceuticals |
Company profile

Pharmos Corporation (Pharmos) is a biopharmaceutical company that discovers and develops therapeutics to treat a range of metabolic and nervous system disorders, including gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. Pharmos owns the rights to both R and S Tofisopam. These are the two enantiomers of racemic tofisopam that has been used outside the United States. The Company’s primary focus is on the development and partnering of Levotofisopam and Dextofisopam. The Company's product Dextofisopam is used for the treatment of irritable bowel syndrome (IBS). Dextofisopam is the R enantiomer of racemic tofisopam. Levotofisopam is the S-enantiomer of the racemic mixture RS-tofisopam.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.